329794-09-4Relevant articles and documents
Discovery of BAY-985, a Highly Selective TBK1/IKK? Inhibitor
Lefranc, Julien,Schulze, Volker Klaus,Hillig, Roman Christian,Briem, Hans,Prinz, Florian,Mengel, Anne,Heinrich, Tobias,Balint, Jozsef,Rengachari, Srinivasan,Irlbacher, Horst,St?ckigt, Detlef,B?mer, Ulf,Bader, Benjamin,Gradl, Stefan Nikolaus,Nising, Carl Friedrich,Von Nussbaum, Franz,Mumberg, Dominik,Panne, Daniel,Wengner, Antje Margret
supporting information, p. 601 - 612 (2020/02/04)
The serine/threonine kinase TBK1 (TANK-binding kinase 1) and its homologue IKK? are noncanonical members of the inhibitor of the nuclear factor κB (IκB) kinase family. These kinases play important roles in multiple cellular pathways and, in particular, in inflammation. Herein, we describe our investigations on a family of benzimidazoles and the identification of the potent and highly selective TBK1/IKK? inhibitor BAY-985. BAY-985 inhibits the cellular phosphorylation of interferon regulatory factor 3 and displays antiproliferative efficacy in the melanoma cell line SK-MEL-2 but showed only weak antitumor activity in the SK-MEL-2 human melanoma xenograft model.
HETEROARYLBENZIMIDAZOLE COMPOUNDS
-
Page/Page column 326, (2017/07/06)
The present invention covers heteroarylbenzimidazole compounds of general formula (I) in which R1, R2, R3, R4 and R5 are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of hyperproliferative and/or inflammatory disorders, as a sole agent or in combination with other active ingredients.
1,3-THIAZOLE-5-CARBOXAMIDES USEFUL AS CANCER CHEMOTHERAPEUTIC AGENTS
-
Page/Page column 48, (2008/06/13)
This invention relates to novel 1, 3- thiazole-5 -carboxamide compounds of formula (I), pharmaceutical compositions containing such compounds, and the use of those compounds or compositions as cancer chemotherapeutic agents.